• EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

  NCT04822818

  CompletedInterventionalPhase 3Updated Dec 28, 2022
• Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort

  NCT04344782

  Unknown statusInterventionalPhase 2Updated Apr 17, 2020
• Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

  NCT04275414

  CompletedInterventionalPhase 2Updated Sep 14, 2020
• Bevacizumab in Patients With Severe Covid-19

  NCT04305106

  Unknown statusInterventionalPhase 3Updated Jun 27, 2023
• Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

  NCT04954014

  TerminatedInterventionalPhase 2Updated Sep 5, 2021
• Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer

  NCT02250118

  TerminatedInterventionalPhase 1Updated Nov 6, 2017

ClinicalTrials.gov ID

NCT07089719

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

21Estimated

Last Update Posted

Jul 28, 2025Actual

Start Date

Oct 1, 2025Estimated

Primary Completion Date

Jan 1, 2028Estimated

Completion Date

May 1, 2028Estimated

Official Title

Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

Brief Summary

The aim of this research is to evaluate an innovative treatment, Bevacizumab, in patients suffering from respiratory complications related to COVID-19. These complications, particularly difficulty breathing (dyspnea) and impaired lung function, are common in some individuals after infection. The study seeks to determine whether Bevacizumab can improve breathing capacity by acting on vascular mechanisms that may be responsible for these issues. A total of 21 patients with these persistent symptoms will be included in the study, with close medical monitoring to assess both the effectiveness of the treatment and its safety.

This research aims to assess the effectiveness and safety of Bevacizumab, a medication known for its anti-angiogenic properties (which prevent the formation of new blood vessels), in patients experiencing persistent respiratory problems after COVID-19 infection. In other words, this research is based on the idea that inhibiting blood vessel formation with Bevacizumab may improve clinical outcomes in patients with severe forms of COVID-19 by reducing vascular complications associated with the infection.

To answer this research question, 21 individuals with persistent respiratory symptoms (significant dyspnea) and reduced lung diffusing capacity (DLCO less than 75% of the predicted value) at least three months after their initial COVID-19 infection will be included. The study is being conducted at Hôpital Européen Georges Pompidou, in Paris.

The total expected duration of the research is 31 months, and each patient's participation will last 7 months, which includes 2 months of treatment (five Bevacizumab injections) followed by five additional months of medical follow-up.

In this research project, we will be evaluating Bevacizumab, an experimental drug in the context of Long COVID. Bevacizumab is a monoclonal antibody used to inhibit angiogenesis (the abnormal formation of new blood vessels). While commonly used in oncology, in this study, its use aims to improve lung function in patients suffering from persistent respiratory complications after COVID-19 infection.

Bevacizumab will be administered as an intravenous infusion. The infusion lasts between 30 and 90 minutes. The dosage is 10 mg/kg every two weeks, for a total of five infusions over a two-month period. Additional follow-up visits will be conducted one month and five months after the end of treatment. Monitoring will include clinical examinations, laboratory tests, and lung function assessments.

• Dyspnea Caused by 2019-nCoV

• Bevacizumab Injection

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients over 18 years, under 90 years
• Social security affiliation
• Good understanding of the French language
• Written informed consent
• DOcumented COVID-19 infection (PCR or CT-scan) more than 3 months before inclusion
• Long COVID suspicion with dyspnea (mMRC > 2 at inclusion)
• DLCO < 75% of predicted value less than 3 months old on the day of screening or to be obtained before Day 1 older than 3 months

Exclusion Criteria:

• Acute COVID-19 infection
• Lung scintigraphy and thoracic CT angiography evaluation to rule out pulmonary embolism less than 3 months old on the day of screening or to be obtained before Day 1 if older than 3 months to exclude Sequelae of pulmonary embolism or lung emphysema in the setting of COPD
• Women of childbearing potential
• Myocardial infarction or stroke less than 3 months before screening
• Uncontrolled hypertension (> 140/90 at inclusion in the study)
• Proteinuria/creatinuria ratio > 1 g/mmol at baseline DFG < 30 ml/min
• History of malignant hypertension
• Previous osteonecrosis
• History of Aneurysm and artery dissections
• Active cancer
• Known hypersensitivity to bevacizumab or any ingredient in its formulation, including non-medicinal ingredients, or a component of the container
• Hypersensitivity to Chinese Hamster Ovary (CHO) cell product or other recombinant human or humanized antibodies
• History of radiotherapy
• History of bisphosphonates treatment
• Surgery in 28 days before inclusion
• Participation in another interventional study or being in the exclusion period at the end of a previous study
• Patient unable or unwilling to comply with the follow up schedule (at the investigator's discretion)
• Pregnant or breastfeeding women
• Vulnerable populations (patient under gardianship, curatorship, deprived of liberty)
• Patient on AME (State medical aid)

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Collaborators

Ministry of Health, FranceOTHER_GOV

ANRS, Emerging Infectious DiseasesOTHER_GOV

sven.gunther@aphp.fr0156095451 ext. +33